Correction: Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.(Cancers, (2022), 14, (1510), 10.3390/cancers14061510)

Selinde S. Wind, Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, David Bonnel, Raphael Legouffe, Florian Barré, Marcel W. Bekkenk, Ellen R. M. de Haas, Koen D. Quint, Harald Schnidar, Melanie Rolli, Henk Johan Streefkerk, Jacobus BurggraafMaarten H. Vermeer, Robert Rissmann*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic


The authors wish to make the following corrections to this paper [1]: 1. ‘Harald Schnidar’ was not included as an author in the published article and he was added as the co-author including his affiliation 8. The corrected Author Contributions Statement was updated as follows:.
Original languageEnglish
Article number1485
Issue number5
Publication statusPublished - 1 Mar 2023

Cite this